ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion

Jun 25, 10:00 AM
Headliner
Share
Subscribe
In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO contracting models for financial transparency, and Eli Lilly's acquisition strategy.
Share
Subscribe
Next
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
Top episodes
AI in Clinical Trials - A Long, But Promising Road Ahead
by Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
by Applied Clinical Trials
Diversity in Clinical Trials: The Need to Take Action
by Applied Clinical Trials